OrbiMed Advisors XERS Position
Exited4-Fund ConvergenceOrbiMed Advisors exited their position in Xeris Biopharma Holdings, Inc. (XERS) in Q4 2025, after holding the stock for 8 quarters.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
XERS is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Full company profile →Short Interest
9.8%
7.0 days to cover
OrbiMed Advisors XERS Position History
Frequently Asked Questions
Does OrbiMed Advisors own XERS?
No. OrbiMed Advisors exited their position in Xeris Biopharma Holdings, Inc. (XERS) in Q4 2025. They previously held the stock for 8 quarters.
How many hedge funds own XERS?
4 specialist biotech hedge funds currently hold XERS, including Driehaus Capital, Deerfield Management, Redmile Group and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy XERS?
OrbiMed Advisors's position in XERS was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's XERS position increasing or decreasing?
OrbiMed Advisors completely exited their XERS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
XERSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →